Lactam compounds and their use as inhibitors of serine proteases and method
申请人:Bristol-Myers Squibb Company
公开号:US06344450B1
公开(公告)日:2002-02-05
Lactam inhibitors are provided which have the structure
X is
wherein
Y is O or S and R4 is
R7O— or R8
and R1, R2, R3, R5, R6, R7, and R8, are as defined herein. These compounds are inhibitors of Factor Xa and thus are useful as anticoagulants, and are inhibitors of tryptase and thus are useful in treating asthma. Methods for treating cardiovascular diseases associated with thromboses and for treating asthma and related diseases are also provided.
Dual Metalloprotease Inhibitors. 6. Incorporation of Bicyclic and Substituted Monocyclic Azepinones as Dipeptide Surrogates in Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitors
作者:Jeffrey A. Robl、Maria P. Cimarusti、Ligaya M. Simpkins、Baerbel Brown、Denis E. Ryono、J. Eileen Bird、Magdi M. Asaad、Thomas R. Schaeffer、Nick C. Trippodo
DOI:10.1021/jm950677a
日期:1996.1.1
series of substitutedmonocyclic and bicyclic azepinones were incorporated as dipeptide surrogates in mercaptoacetyl dipeptides with the desire to generate a single compound which would potently inhibit both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). Many of these compounds displayed excellent potency against both enzymes. Two of the most potent compounds, monocyclic azepinone